28-Jan-2019 | Zion Market Research
Zion Market Research has published a new report titled “Autoinjectors Market by Type (Reusable Autoinjectors and Disposable Autoinjectors), by Technology (Manual Autoinjectors and Automated Autoinjectors), by Therapy (Multiple Sclerosis, Rheumatoid Arthritis, Anaphylaxis, Diabetes, and Others), by Design (Customized Autoinjectors and Standardized Autoinjectors), and by End-User (Hospital & Clinics and Home Care Settings): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019—2025”. According to the report, the global autoinjectors market was valued at approximately USD 29.56 billion in 2018 and is expected to generate around USD 137.03 billion by 2025, at a CAGR of around 24.7% between 2019 and 2025.
Autoinjectors are medical devices designed to administer a dose of a specific drug to patients. Autoinjectors are proposed for self-administration of drug dosage by patients. They are easy to use and can be operated by even an untrained person. Epinephrine autoinjectors are often recommended to people at the risk of anaphylaxis. SureClick autoinjector is an amalgamation of medications Aranesp or Enbrel, which treats anemia or rheumatoid arthritis. In the military, autoinjectors are often used to guard personnel from chemical combat agents.
Browse the full “Autoinjectors Market by Type (Reusable Autoinjectors and Disposable Autoinjectors), by Technology (Manual Autoinjectors and Automated Autoinjectors), by Therapy (Multiple Sclerosis, Rheumatoid Arthritis, Anaphylaxis, Diabetes, and Others), by Design (Customized Autoinjectors and Standardized Autoinjectors), and by End-User (Hospital & Clinics and Home Care Settings): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019—2025” Report at https://www.zionmarketresearch.com/report/autoinjectors-market
The increasing adoption of targeted therapy, growing anaphylaxis incidences, growing regulatory approvals, simplifying self-administration, increasing biologics use for drug delivery, rising cancer and diabetes cases, advantageous reimbursement scenario, and the availability of generic autoinjectors are likely to be major factors driving the growth of the global autoinjectors market. Patent expiry of current products and technological improvements related to autoinjectors due to an increased focus on research and development is anticipated to further fuel the autoinjectors market globally in the future. Nonetheless, the growing use of alternative modes of drug delivery, infections and injuries caused due to needle-stick, and multiple regulatory might restrict the growth of the global autoinjectors market in the upcoming years.
The global autoinjectors market is split based on type, technology, therapy, design, and end-user. By type, the autoinjectors market is segmented into reusable autoinjectors and disposable autoinjectors. Disposable autoinjectors are likely to grow rapidly over the forecast time period. The technology segment includes manual autoinjectors and automated autoinjectors. The therapy segment includes multiple sclerosis, rheumatoid arthritis, anaphylaxis, diabetes, and others. The design segment includes customized autoinjectors and standardized autoinjectors. The end-user segment includes hospital and clinics and home care settings. Home care settings are expected to hold the largest share of the global market, owing to the rising use of autoinjectors for self-administration of drugs.
By region, the North American autoinjectors market is likely to lead over the forecast time period. This can be attributed to the growing incidence of anaphylaxis in the U.S., increasing number of FDA approvals, and rising prevalence of chronic and autoimmune disorders, increased biologics use for drug delivery, and growing use of self-administered drugs. Europe is likely to emerge as the second largest market in the future, owing to the growing geriatric population, increasing cancer and diabetes cases, advantageous reimbursement scenario, and growing prescriptions for adrenaline autoinjectors. The Asia Pacific region is anticipated to propagate at a speedy rate over the forecast time period, due to the increasing cases of chronic disorders, such as diabetes, growing awareness regarding self-administration of drugs, increasing cases of rheumatoid arthritis, and the availability of generic versions of autoinjectors.
Some key players of the global autoinjectors market include Eli Lilly, Abbvie, Biogen, Teva, Mylan, Merck, Ypsomed, SHL Group, Becton Dickinson and Company, and Novartis, among others.
This report segments the global autoinjectors market into:
Global Autoinjectors Market: By Type
Global Autoinjectors Market: By Technology
Global Autoinjectors Market: By Therapy
Global Autoinjectors Market: By Design
Global Autoinjectors Market: By End-User
Global Autoinjectors Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651